Holen Sie sich die Stockscreener-App
16.15
0.94%
0.15
Vorhandelsmarkt:
16.16
0.01
+0.06%
Schlusskurs vom Vortag:
$16.00
Offen:
$15.95
24-Stunden-Volumen:
1.05M
Relative Volume:
0.61
Marktkapitalisierung:
$2.86B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-382.71M
KGV:
-6.1641
EPS:
-2.62
Netto-Cashflow:
$-325.64M
1W Leistung:
+0.94%
1M Leistung:
+8.75%
6M Leistung:
-34.80%
1J Leistung:
-41.29%
1-Tages-Spanne:
$15.86
$16.70
1-Wochen-Bereich:
$15.50
$16.70
52-Wochen-Spanne:
$12.72
$34.47
Immunovant Inc Stock (IMVT) Company Profile
Firmenname
Immunovant Inc
Sektor
Branche
Telefon
917-580-3099
Adresse
320 WEST 37TH STREET, NEW YORK, NY
Vergleichen Sie IMVT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
16.15 | 2.86B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-03 | Eingeleitet | Jefferies | Hold |
| 2025-01-03 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-09 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-03-13 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | JP Morgan | Overweight |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-13 | Hochstufung | UBS | Neutral → Buy |
| 2023-09-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Eingeleitet | BofA Securities | Buy |
| 2023-04-25 | Eingeleitet | Citigroup | Buy |
| 2023-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2023-02-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-08-03 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-01 | Herabstufung | Stifel | Buy → Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-10-12 | Eingeleitet | Guggenheim | Buy |
| 2020-10-08 | Eingeleitet | Stifel | Buy |
| 2020-10-02 | Eingeleitet | Credit Suisse | Outperform |
| 2020-08-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-07-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-24 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Immunovant Inc Aktie (IMVT) Neueste Nachrichten
GAMMA Investing LLC Buys 5,229 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Learn to Evaluate (IMVT) using the Charts - news.stocktradersdaily.com
Immunovant, Inc. (NASDAQ:IMVT) Receives $38.33 Consensus Target Price from Brokerages - Defense World
Immunovant: Navigating The Complexities Of The FcRn Landscape (Downgrade) - Seeking Alpha
Cantor Fitzgerald Forecasts Immunovant FY2027 Earnings - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Shares Sold by Wellington Management Group LLP - Defense World
Two Sigma Advisers LP Buys New Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Ameriprise Financial Inc. Makes New Investment in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), Dexcom (DXCM) and Immunovant (IMVT) - The Globe and Mail
Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Long Term Trading Analysis for (IMVT) - news.stocktradersdaily.com
Leerink Partnrs Estimates Immunovant FY2030 Earnings - Defense World
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus - MSN
Immunovant price target lowered to $35 from $51 at H.C. Wainwright - TipRanks
Immunovant’s Promising Future: Buy Rating Backed by Strategic Advancements and Strong Cash Position - TipRanks
Immunovant Inc reports results for the quarter ended March 31Earnings Summary - TradingView
H.C. Wainwright Adjusts Price Target for Immunovant (IMVT) Amid Future Prospects | IMVT Stock News - GuruFocus
Immunovant Insiders Sell US$5.9m Of Stock, Possibly Signalling Caution - simplywall.st
Immunovant (NASDAQ:IMVT) Shares Gap Up After Better-Than-Expected Earnings - Defense World
Immunovant, Inc. Reports Strategic Progress and Financial Results - TipRanks
IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm - The Malaysian Reserve
Immunovant, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 - marketscreener.com
Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence By Stocktwits - Investing.com India
Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence - MSN
Immunovant, Inc. SEC 10-K Report - TradingView
Immunovant (IMVT) Secures Strong Financial Position with $714 Million in Cash | IMVT Stock News - GuruFocus
Immunovant's Fiscal Q4 Net Loss Widens - marketscreener.com
Earnings Flash (IMVT) IMMUNOVANT INC. Reports Q4 Loss $0.64 Per Share, vs. FactSet Est of $-0.71 - marketscreener.com
Immunovant's Clinical Trials Show 74% Success in Myasthenia Gravis, Advancing 6 Disease Programs - Stock Titan
Immunovant (IMVT) to Release Earnings on Wednesday - Defense World
Bank of America Corp DE Buys 114,511 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
(IMVT) Trading Advice - news.stocktradersdaily.com
IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm - Business Wire
Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) Target Price at $38.33 - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by Northern Trust Corp - Defense World
Is Immunovant, Inc. (IMVT) The Most Undervalued Stock With Smart Money Ratings? - Insider Monkey
The Manufacturers Life Insurance Company Has $889,000 Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Transcript : Immunovant, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 04 - marketscreener.com
Smart Money Ratings For 20 Most Undervalued Stocks - Insider Monkey
Immunovant Inc (NASDAQ: IMVT) Is The Among Hot Stock Right Now - Stocksregister
Dimensional Fund Advisors LP Sells 58,463 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back? - Insider Monkey
Raymond James Financial Inc. Buys Shares of 20,382 Immunovant, Inc. (NASDAQ:IMVT) - Defense World
11 Stocks That Will Bounce Back According to Analysts - Insider Monkey
Investor’s Delight: Immunovant Inc (IMVT) Closes Weak at 15.22, Down -3.67 - DWinneX
Ins & Outs: Biopharma players shuffle c-suite ranks - BioProcess International
(IMVT) Investment Analysis - news.stocktradersdaily.com
Immunovant, Inc. (NASDAQ:IMVT) Shares Acquired by Wells Fargo & Company MN - Defense World
A company insider recently sold 1,925 shares of Immunovant Inc [IMVT]. Should You Sale? - knoxdaily.com
IMVT’s Stock Market Adventure: -34.80% YTD Growth Amidst Volatility - investchronicle.com
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial - openPR.com
Finanzdaten der Immunovant Inc-Aktie (IMVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):